Potential therapeutic mechanisms of stable prostacyclin (PGI2)-mimetics in severe peripheral vascular disease

Müller, B.; Krais, T.; Stürzebecher, S; Witt, Werner; Schillinger, E.; Baldus, B.

doi:10.1016/s0031-6989(88)80389-8

Cited by 3 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…32,74 One of these studies was included in the current review, 32 but the other was excluded because the unit of allocation was wards as opposed to patients or lesions. 74 For therapeutic interventions, three studies assessing the effectiveness of topical agents with antimicrobial properties were included, [75][76][77] and also one evaluation of a systemic agent (oral metronidazole). 78 These studies were excluded from the current review due to use of a before/after study design, 78 wards as the unit of allocation, 76 absence of wound-healing outcomes 77 and confounding treatment regimens.…”

Section: Systematic Review Of the Management Of Pressure Ulcersmentioning

confidence: 99%

“…74 For therapeutic interventions, three studies assessing the effectiveness of topical agents with antimicrobial properties were included, [75][76][77] and also one evaluation of a systemic agent (oral metronidazole). 78 These studies were excluded from the current review due to use of a before/after study design, 78 wards as the unit of allocation, 76 absence of wound-healing outcomes 77 and confounding treatment regimens. 75 The general conclusions were that the area of topical applications requires further research, and that a consensus in outcome measurement is needed.…”

Section: Systematic Review Of the Management Of Pressure Ulcersmentioning

confidence: 99%

“…In one RCT, Brock and co-workers 75 (a duplicate of the study by Muller 76 ) randomised 109 diabetic patients with ischaemic lesions to either intravenous iloprost (n = 56) for 6 h/day at an individually tolerated dose up to 2 ng/kg per minute or to a placebo (n = 53). In addition, all patients received intensive topical therapy (debridement, antibiotics and dressings).…”

Section: Iloprost Versus Placebomentioning

confidence: 99%

“…The single trial of iloprost 75,76 and trials of PGE 1 and PGE 1 -CD 78 have shown positive results in that Discussion intravenous infusions of iloprost resulted in greater ulcer healing than did placebo, and PGE 1 and PGE 1 -CD resulted in a significant reduction in ulcer area. However, the poor quality of these trials, namely the subjective outcome measures used, and a lack of blinded outcome assessment, precludes any definitive conclusions being drawn about the effectiveness of prostaglandins as a treatment for diabetic foot ulcers.…”

Section: Prostaglandinsmentioning

confidence: 99%

See 3 more Smart Citations

Systematic reviews of wound care management: (3) antimicrobial agents for chronic wounds; (4) diabetic foot ulceration

O’Meara

Cullum

Majid

et al. 2001

Health Technol Assess

122

112

View full text Add to dashboard Cite

reviews of wound care management: (3) antimicrobial agents for chronic wounds; (4) diabetic foot ulceration. Health Technol Assess 2000;4(21). Health Technology Assessment is indexed in Index Medicus/MEDLINE and Excerpta Medica/ EMBASE. Copies of the Executive Summaries are available from the NCCHTA website (see overleaf). NHS R&D HTA Programme T he overall aim of the NHS R&D Health Technology Assessment (HTA) programme is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and work in the NHS. Research is undertaken in those areas where the evidence will lead to the greatest benefits to patients, either through improved patient outcomes or the most efficient use of NHS resources. The Standing Group on Health Technology advises on national priorities for health technology assessment. Six advisory panels assist the Standing Group in identifying and prioritising projects. These priorities are then considered by the HTA Commissioning Board supported by the National Coordinating Centre for HTA (NCCHTA). This report is one of a series covering acute care, diagnostics and imaging, methodology, pharmaceuticals, population screening, and primary and community care. It was identified as a priority by the Pharmaceutical Panel and funded as project number 93/29/01. The views expressed in this publication are those of the authors and not necessarily those of the Standing Group, the Commissioning Board, the Panel members or the Department of Health. The editors wish to emphasise that funding and publication of this research by the NHS should not be taken as implicit support for the recommendations for policy contained herein. In particular, policy options in the area of screening will be considered by the National Screening Committee. This Committee, chaired by the Chief Medical Officer, will take into account the views expressed here, further available evidence and other relevant considerations. Reviews in Health Technology Assessment are termed 'systematic' when the account of the search, appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

show abstract

Section: Systematic Review Of the Management Of Pressure Ulcersmentioning

confidence: 99%

Section: Systematic Review Of the Management Of Pressure Ulcersmentioning

confidence: 99%

Section: Iloprost Versus Placebomentioning

confidence: 99%

Section: Prostaglandinsmentioning

confidence: 99%

See 2 more Smart Citations

Systematic reviews of wound care management: (3) antimicrobial agents for chronic wounds; (4) diabetic foot ulceration

O’Meara

Cullum

Majid

et al. 2001

Health Technol Assess

122

112

View full text Add to dashboard Cite

show abstract

“…Despite their potent antithrombotic effects in several animal models ( van der Giessen et al , 1988 ; Takiguchi et al , 1992 ; Kotze et al , 1993 ), TP‐receptor antagonists have been reported to show only poor antithrombotic effects in the clinical trials ( Serruys et al , 1991 ; Norris et al , 1996 ). On the other hand, the clinical application of IP‐receptor agonists has been limited to pulmonary hypertension or moderate thrombotic disease because of their potent vasodilating effects ( Muller et al , 1988 ; Nagaya et al , 1999 ).…”

Section: Introductionmentioning

confidence: 99%

Effects of TRA‐418, a novel TP‐receptor antagonist, and IP‐receptor agonist, on human platelet activation and aggregation

Miyamoto

Yamada

Ikezawa

et al. 2003

British J Pharmacology

View full text Add to dashboard Cite

1 {4-[2-(1,1-Diphenylethylsulfanyl)-ethyl]-3,4-dihydro-2H-benzo [1,4]oxazin-8-yloxy}-acetic acid NMethyl-D-glucamine salt (TRA-418) has both thromboxane A 2 (TP)-receptor antagonist and prostacyclin (IP)-receptor agonist properties. The present study examined the advantageous effects of TRA-418 based on the dual activities, over an agent having either activity alone and also the difference in the effects of TRA-418 and a glycoprotein aIIb/b3 integrin (GPIIb/IIIa) inhibitor. 2 TRA-418 inhibited platelet GPIIb/IIIa activation as well as P-selectin expression induced by adenosine 5 0 -diphosphate, thrombin receptor agonist peptide 1 -6 (Ser-Phe-Leu-Leu-Arg-Asn-NH 2 ), and U-46619 in the presence of epinephrine (U-46619 þ epinephrine). TRA-418 also inhibited platelet aggregation induced by those platelet-stimulants in Ca 2 þ chelating anticoagulant, citrate and in nonchelating anticoagulant, D-phenylalanyl-L-prolyl-L-arginyl-chloromethyl ketone (PPACK). 3 The TP-receptor antagonist SQ-29548 inhibited only U-46619 þ epinephrine-induced GPIIb/IIIa activation, P-selectin expression, and platelet aggregation. 4 The IP-receptor agonist beraprost sodium inhibited platelet activation. Beraprost also inhibited platelet aggregation induced by platelet stimulants we tested in citrate and in PPACK. 5 The GPIIb/IIIa inhibitor abciximab blocked GPIIb/IIIa activation and platelet aggregation. However, abciximab showed slight inhibitory effects on P-selectin expression. 6 TRA-418 is more advantageous as an antiplatelet agent than TP-receptor antagonists or IPreceptor agonists separately used. TRA-418 showed a different inhibitory profile from abciximab in the effects on P-selectin expression.

show abstract

The wound/burn guidelines – 3: Guidelines for the diagnosis and treatment for diabetic ulcer/gangrene

Isei

Abe

Nakanishi

et al. 2016

The Journal of Dermatology

View full text Add to dashboard Cite

We aimed to prepare guidelines for the management of diabetic ulcer/gangrene with emphasis on the diagnosis and treatment of skin symptoms. They serve as a tool to improve the quality of the diagnosis and treatment in each patient and, further, to improve the level of the care for diabetic ulcer in Japan by systematically presenting evidence-based recommendations for clinical judgments by incorporating various viewpoints.

show abstract

Potential therapeutic mechanisms of stable prostacyclin (PGI2)-mimetics in severe peripheral vascular disease

Cited by 3 publications

References 0 publications

Systematic reviews of wound care management: (3) antimicrobial agents for chronic wounds; (4) diabetic foot ulceration

Systematic reviews of wound care management: (3) antimicrobial agents for chronic wounds; (4) diabetic foot ulceration

Effects of TRA‐418, a novel TP‐receptor antagonist, and IP‐receptor agonist, on human platelet activation and aggregation

The wound/burn guidelines – 3: Guidelines for the diagnosis and treatment for diabetic ulcer/gangrene

Contact Info

Product

Resources

About